Volume 74, Pages S88-S93 (December 2008)

Slides:

Advertisements

Similar presentations

Volume 68, Pages S24-S28 (July 2005)

Advertisements

RenaGel®, a nonabsorbed calcium- and aluminum-free phosphate binder, lowers serum phosphorus and parathyroid hormone Eduardo A. Slatopolsky, Steven K.

Volume 67, Pages S1-S7 (June 2005)

Chapter 3.1: Diagnosis of CKD–MBD: biochemical abnormalities

Summary of KDIGO 2012 CKD Guideline: behind the scenes, need for guidance, and a framework for moving forward Adeera Levin, Paul E. Stevens Kidney International

KDIGO Clinical Practice Guideline for Lipid Management in CKD: summary of recommendation statements and clinical approach to the patient Christoph Wanner,

Anemia management in chronic kidney disease

American Journal of Kidney Diseases

Mitchell H. Rosner, W. Kline Bolton Kidney International

KDOQI Clinical Practice Guideline for Diabetes and CKD: 2012 Update

Volume 79, Issue 9, Pages (May 2011)

Volume 83, Issue 3, Pages (March 2013)

FGF23 or PTH: which comes first in CKD ?

Chapter 3.1: Diagnosis of CKD–MBD: biochemical abnormalities

From secondary to primary prevention of progressive renal disease: The case for screening for albuminuria Paul E. De Jong, Barry M. Brenner Kidney International

Pieter Evenepoel, Myles Wolf Kidney International

RenaGel®, a nonabsorbed calcium- and aluminum-free phosphate binder, lowers serum phosphorus and parathyroid hormone Eduardo A. Slatopolsky, Steven K.

Calcium balance in normal individuals and in patients with chronic kidney disease on low- and high-calcium diets David M. Spiegel, Kate Brady Kidney.

Prehypertension and chronic kidney disease: the ox or the plow?

Status of chronic kidney disease prevention programs: International Federation of Kidney Foundation Members 2005/2007 Joanna M. Smith, Susan A. Mott,

Reassessment of the care of the patient with chronic kidney disease

Bone Disease in Elderly Individuals With CKD

Volume 80, Issue 10, Pages (November 2011)

Progression of renal failure and hypertensive nephrosclerosis

Volume 63, Pages S88-S90 (June 2003)

John P. Middleton, Patrick H. Pun Kidney International

M. Fukagawa, S. Nakanishi, J.J. Kazama Kidney International

Haiyan Wang, Luxia Zhang, Jicheng Lv Kidney International

Chapter 3: Management of progression and complications of CKD

Guideline 1: Detection and evaluation of HCV in CKD

Yasuhiro Hamada, Masafumi Fukagawa Kidney International

Jeffrey C. Fink, Glenn M. Chertow Kidney International

Volume 76, Pages S50-S99 (August 2009)

Volume 71, Issue 1, Pages (January 2007)

Volume 70, Pages S21-S25 (December 2006)

The progression of chronic kidney disease: A 10-year population-based study of the effects of gender and age B.O. Eriksen, O.C. Ingebretsen Kidney International

Treatment of hyperphosphatemia in patients with chronic kidney disease on maintenance hemodialysis: Results of the CARE study Wajeh Y. Qunibi, Charles.

Steven G. Coca, Swathi Singanamala, Chirag R. Parikh

Volume 66, Pages S13-S17 (September 2004)

Comorbidity and confounding in end-stage renal disease

D. Batlle, P. Ramadugu, M.J. Soler Kidney International

A new era in phosphate binder therapy: What are the options?

Volume 74, Issue 3, Pages (August 2008)

Volume 70, Issue 11, Pages (December 2006)

Volume 79, Pages S20-S23 (April 2011)

The epidemiology of chronic kidney disease

Use of vitamin D in chronic kidney disease patients

Volume 87, Issue 2, Pages (February 2015)

Clinical relevance of FGF-23 in chronic kidney disease

Correction to "Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate.

The calcium–phosphorus in guidelines for CKD-MBD

Volume 70, Issue 12, Pages (December 2006)

Volume 68, Pages S24-S28 (July 2005)

Volume 73, Issue 12, Pages (June 2008)

Volume 56, Pages S31-S37 (December 1999)

Methods for guideline development

Volume 87, Issue 1, Pages (January 2015)

Volume 85, Issue 1, Pages (January 2014)

A practical approach to the treatment of depression in patients with chronic kidney disease and end-stage renal disease S. Susan Hedayati, Venkata Yalamanchili,

Secondary hyperparathyroidism is associated with higher mortality in men with moderate to severe chronic kidney disease C.P. Kovesdy, S. Ahmadzadeh,

Volume 67, Pages S55-S62 (January 2005)

Taking a public health approach to the prevention of end-stage renal disease: The NKF Singapore Program Sylvia Paz B. Ramirez, Stephen I-Hong Hsu, William.

Phosphate binders on iron basis: A new perspective?

Volume 55, Pages S3-S16 (June 1999)

Volume 80, Issue 10, Pages (November 2011)

Evaluation of the Losartan in Hemodialysis (ELHE) Study

In chronic kidney disease staging the use of the chronicity criterion affects prognosis and the rate of progression B.O. Eriksen, O.C. Ingebretsen Kidney.

O.M. Gutiérrez, T. Isakova, D.L. Andress, A. Levin, M. Wolf

The prevalence of hematologic and metabolic abnormalities during chronic kidney disease stages in different ethnic groups S.J. Barbour, L. Er, O. Djurdjev,

Volume 64, Pages S131-S136 (November 2003)

Presentation transcript:

Volume 74, Pages S88-S93 (December 2008) Hyperphosphatemia and hyperparathyroidism in incident chronic kidney disease patients Ana M. Ramos, Marta Albalate, Silvia Vázquez, Carlos Caramelo, Jesús Egido, Alberto Ortiz Kidney International Volume 74, Pages S88-S93 (December 2008) DOI: 10.1038/ki.2008.543 Copyright © 2008 International Society of Nephrology Terms and Conditions

Figure 1 Serum calcium (a) decreases whereas serum phosphate (b) and PTH (c) levels increase with progression of CKD stage (mean, s.d.). Broken horizontal lines indicate the range recommended by Spanish Society of Nephrology (SEN) CKD-MBD guidelines.6 Kidney International 2008 74, S88-S93DOI: (10.1038/ki.2008.543) Copyright © 2008 International Society of Nephrology Terms and Conditions

Figure 2 Percentage of patients outside the guidelines, at baseline and at 1 year of follow-up. Ca: Calcium >9.5mg per 100ml; P: phosphate >4.6mg per 100ml for CKD 3, 4 and >5mg per 100ml for CKD 5; iPTH >65pg/ml for CKD 3, >110pg/ml for CKD 4 and >300pg/ml for CKD 5; LDL: LDL cholesterol >100mg per 100ml for primary prevention and >70mg per 100ml for secondary prevention; uric acid >7mg per 100ml. 22 CKD 3, 38 CKD 4, and 9 CKD 5 patients were analyzed. Kidney International 2008 74, S88-S93DOI: (10.1038/ki.2008.543) Copyright © 2008 International Society of Nephrology Terms and Conditions